Royal Biologics Announces U.S. Commercial Launch of BIOINCYTE™ PRFM
14 févr. 2023 08h00 HE
|
Royal Biologics
HACKENSACK, N.J., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Royal Biologics, a company specializing in Advanced Cellular Technologies & Enhanced Autologous Solutions, today announces the commercial...
Royal Biologics Announces FDA 510K Approval and U.S. Commercial Launch of the MAXX™-BMC Bone Marrow Aspirate Concentration System
01 juin 2022 09h00 HE
|
Royal Biologics
HACKENSACK, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Royal Biologics (Hackensack, NJ), a company specializing in Advanced Cellular Technologies & Enhanced Autologous Healing, announces today the...
Royal Biologics Announces U.S. Commercial Launch of Advanced-Cell™, an Advanced Bone Grafting and Fusion Convenience Kit
26 avr. 2022 13h00 HE
|
Royal Biologics (royalbiologics.com)
HACKENSACK, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Royal Biologics (Hackensack, NJ), a company specializing in Advanced Cellular & Autologous Technologies for Enhanced Healing, today announced...
Royal Biologics Announces FDA Approval of the Maxx™ Concentration System.
08 sept. 2021 09h12 HE
|
Royal Biologics
HACKENSACK, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Royal Biologics, an ortho-biologics company focused on Autologous and Live Cellular solutions, has announced FDA 510K approval of their Maxx™-PRP...